osimertinib
astrazeneca
['lcsm,(-blcsm)']
phase ii neoadjuvant osi presented by , resulted in a 15% mpr #asco23 #lcsm 
#HemeOnc @LombardiCancer |@EmoryDeptofMed @GradyHealth @tulanemedicine |#MedEd #clinicaltrials #disparities #lcsm 🎶🎤|🐱mom|she/her⚜️🏠#504 tweetsmyown